| Customization: | Available |
|---|---|
| CAS No.: | 171099-57-3 |
| Formula: | C86h97cl3n10o26 |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Oritavancin (Orbactiv)
CAS: 171099-57-3
Appearance: White powder
Certification: ISO 9001:2015; GMP
Specification: USP-40
Oritavancin, marketed under the brand name Orbactiv, is an innovative antibiotic approved by the FDA for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). It stands out as the first and only single-dose antibiotic treatment for ABSSSIs, where just one infusion completes the entire therapy. This approval marks a significant advancement in the treatment of bacterial skin infections, far exceeding current clinical standards.
Oritavancin injection (IV) is FDA-approved for adult patients with ABSSSIs caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). As a next-generation semi-synthetic glycopeptide antibiotic, following earlier glycopeptides such as vancomycin and teicoplanin, Oritavancin offers a durable antibacterial effect and is specifically designed to treat Gram-positive bacterial infections, including MRSA-related ABSSSIs.
Compared to other therapies, Oritavancin presents several advantages:
Our research team has successfully leveraged vancomycin-producing strains as the starting point to reconstruct the biosynthetic system for the precursor A82846B using synthetic biology techniques. This breakthrough has achieved a fermentation yield of over 1 gram per liter in shake flasks, marking a significant technological advancement in Oritavancin production.
){kind=link}